Masayuki Arakawa, Tomoya Mita, Kosuke Azuma, Chie Ebato, Hiromasa Goto, Takashi Nomiyama, Yoshio Fujitani, Takahisa Hirose, Ryuzo Kawamori, Hirotaka Watada
Index: Diabetes 59(4) , 1030-7, (2010)
Full Text: HTML
Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis.After continuous infusion of low (300 pmol . kg(-1) . day(-1)) or high (24 nmol . kg(-1) . day(-1)) dose of exendin-4 in C57BL/6 or apolipoprotein E-deficient mice (apoE(-/-)), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes.Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE(-/-) mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-alpha and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-kappaB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI(14-22), a protein kinase A-specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b.Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Exenatide acetate salt
CAS:141758-74-9 |
C184H282N50O60S |
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonis...
2006-01-01 [Hepatology 43(1) , 173-81, (2006)] |
Effects of exenatide (exendin-4) on glycemic control and wei...
2005-05-01 [Diabetes Care 28(5) , 1092-100, (2005)] |
Exendin-4 stimulates both beta-cell replication and neogenes...
1999-12-01 [Diabetes 48(12) , 2270-6, (1999)] |
Isolation and characterization of exendin-4, an exendin-3 an...
1992-04-15 [J. Biol. Chem. 267 , 7402, (1992)] |
Glucagon-like peptide-1 stimulates luteinizing hormone-relea...
1998-03-15 [J. Clin. Invest. 101 , 1334-1341, (1998)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved